Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
Authors:
- Ariel IsaacsAIAriel Isaacs
- Zheyi LiZLZheyi Li
- Stacey T. M. CheungSCStacey T. M. Cheung
- Danushka K. WijesundaraDWDanushka K. Wijesundara
- Christopher L. D. McMillanChristopher L. D. McMillan
- Naphak ModhiranNMNaphak Modhiran
- Paul R. YoungPYPaul R. Young
- Charani RanasingheCRCharani Ranasinghe
- Daniel WattersonDWDaniel Watterson
- Keith J. ChappellKCKeith J. Chappell
Open Access
Abstract
Subunit vaccines exhibit favorable safety and immunogenicity profiles and can be designed to mimic native antigen structures. However, pairing with an appropriate adjuvant is imperative in order to elicit effective humoral and cellular immune responses. In this study, we aimed to determine an optimal adjuvant pairing with the prefusion form of influenza haemagglutinin (HA) or respiratory syncytial virus (RSV) fusion (F) subunit vaccines in BALB/c mice in order to inform future subunit vaccine adjuvant selection. We tested a panel of adjuvants, including aluminum hydroxide (alhydrogel), QS21, Addavax, Addavax with QS21 (AdQS21), and Army Liposome Formulation 55 with monophosphoryl lipid A and QS21 (ALF55). We found that all adjuvants elicited robust humoral responses in comparison to placebo, with the induction of potent neutralizing antibodies observed in all adjuvanted groups against influenza and in AdQS21, alhydrogel, and ALF55 against RSV. Upon HA vaccination, we observed that none of the adjuvants were able to significantly increase the frequency of CD4+ and CD8+ IFN-γ+ cells when compared to unadjuvanted antigen. The varying responses to antigens with each adjuvant highlights that those adjuvants most suited for pairing purposes can vary depending on the antigen used and/or the desired immune response. We therefore suggest that an adjuvant trial for different subunit vaccines in development would likely be necessary in preclinical studies.Keywords
Funding Information
- National Health and Medical Research Council (APP1144025, APP1125107)
This publication has 87 references indexed in Scilit:
- Protective CD8 T Cell–Mediated Immunity against Influenza A Virus Infection following Influenza Virus–like Particle VaccinationThe Journal of Immunology, 2013
- Respiratory Syncytial Virus Fusion Protein-Induced Toll-Like Receptor 4 (TLR4) Signaling Is Inhibited by the TLR4 Antagonists Rhodobacter sphaeroides Lipopolysaccharide and Eritoran (E5564) and Requires Direct Interaction with MD-2mBio, 2012
- Memory CD4+T-cell–mediated protection depends on secondary effectors that are distinct from and superior to primary effectorsProceedings of the National Academy of Sciences, 2012
- Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensVaccine, 2012
- Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical interventionProceedings of the National Academy of Sciences, 2012
- Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsionExpert Review of Vaccines, 2012
- Cutting Edge: Tissue-Retentive Lung Memory CD4 T Cells Mediate Optimal Protection to Respiratory Virus InfectionThe Journal of Immunology, 2011
- Antibody Response to Polyhistidine-Tagged Peptide and Protein Antigens Attached to Liposomes via Lipid-Linked Nitrilotriacetic Acid in MiceClinical and Vaccine Immunology, 2011
- Dendritic Cell Activation by Recombinant Hemagglutinin Proteins of H1N1 and H5N1 Influenza A VirusesJournal of Virology, 2010
- Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvantCellular and Molecular Life Sciences, 2008